Previous 10 | Next 10 |
Continued Progress on Recurring Revenue, Increased Gross Margin and a Focus on Profitability TORONTO, ON / ACCESSWIRE / May 19, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in geospatial data and artificial intelligence driven software and solutions, announced its financi...
EQ102 selectively blocks IL-15 and IL-21 signaling while preserving signaling of other gamma chain family members Data suggest that selective blockade of IL-15 and IL-21 inhibits the synergistic signaling that mediates NK and T cell responses in multiple immune disorders including celiac ...
2023-05-12 16:15:31 ET Summary EQ sold option to purchase rights for Itolizumab to Ono Pharmaceutical: $26M upfront + program reimbursement + $37M if Ono exercises option right (~Q4 2024). Company now focused on 2 multi-cytokine inhibitor programs: alopecia areata (hair loss from ...
2023-05-11 17:42:48 ET Equillium press release ( NASDAQ: EQ ): Q1 GAAP EPS of -$0.11 beats by $0.07 . Revenue of $8.9M. Research and development (R&D) expenses for the first quarter of 2023 were $9.3 million, compared with $10.8 million for the same period in 2...
$62.0 million cash balance at the end of Q1 2023 expected to provide operating runway into 2025 Presented Phase 1b EQUATE data in aGVHD highlighting rapid and durable rates of overall clinical response, clinical response associated with improved progression-free survival through one year,...
Quarterly revenue increases 38% sequentially TORONTO, ON / ACCESSWIRE / April 28, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in geospatial data and artificial intelligence driven software, announced its financial results today for the fourth quarter and the year ended D...
Itolizumab in combination with systemic corticosteroids was associated with high rates of overall clinical response Response at Day 29 was associated with improved progression-free survival through 1 year Itolizumab is being evaluated in pivotal Phase 3 EQUATOR study in first-line...
2023-03-23 16:39:21 ET Equillium press release ( NASDAQ: EQ ): Q4 GAAP EPS of $0.08 in-line. Revenue of $15.76M beats by $5.36M . Shares +1.22% . For further details see: Equillium GAAP EPS of $0.08 in-line, revenue of $15.76M beats by $5.36M
$71.0 million cash balance at the end of 2022 expected to provide cash runway into 2025 Acquired Bioniz Therapeutics, including two first-in-class clinical-stage assets, EQ101 and EQ102, and proprietary product discovery platform Initiated Phase 2 clinical study of EQ101 in alopec...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtu...
News, Short Squeeze, Breakout and More Instantly...
Q2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutic...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...